A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non–Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation

Ramalingam, 2018, Mechanisms of acquired resistance to first-line osimertinib: preliminary data from the phase III FLAURA study, Ann Oncol, 29, 10.1093/annonc/mdy424.063 Awad, 2016, MET Exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression, J Clin Oncol, 34, 721, 10.1200/JCO.2015.63.4600 Li, 2017, Coexistence of MET exon 14 mutations with EGFR mutations in non-small cell lung cancer, J Clin Oncol, 35, 963, 10.1200/JCO.2017.35.15_suppl.e20636 Suzawa, 2019, Acquired MET Exon 14 alteration drives secondary resistance to epidermal growth factor receptor tyrosine kinase inhibitor in EGFR-mutated lung cancer, JCO Precis Oncol, 3 Schoenfeld, 2020, Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer, Clin Cancer Res, 26, 2654, 10.1158/1078-0432.CCR-19-3563 Sequist, 2020, Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study, Lancet Oncol, 21, 373, 10.1016/S1470-2045(19)30785-5 Guibert, 2017, Characteristics and outcomes of patients with lung cancer harboring multiple molecular alterations: results from the IFCT study biomarkers France, J Thorac Oncol, 12, 963, 10.1016/j.jtho.2017.02.001 Aggarwal, 2019, Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer, JAMA Oncol, 5, 173, 10.1001/jamaoncol.2018.4305 Liu, 2018, Next generation sequencing-based molecular profiling of lung adenocarcinoma using pleural effusion specimens, J Thorac Dis, 10, 2631, 10.21037/jtd.2018.04.125